Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government’s National Research Foundation (NRF).

The ClearCell® FX1 System by Clearbridge BioMedics provide a label-free means of Circulating Tumour Cell (CTC) enrichment that offers a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.

Events
Contact Us for more information